| General Information | |
|---|---|
| ZINC ID | ZINC000299824747 |
| Molecular Weight (Da) | 422 |
| SMILES | CCCCCc1cc(O)cc(OCCCCCCCCCCC(=O)N[C@H](C)CO)c1 |
| Molecular Formula | C25N1O4 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 122.836 |
| HBA | 4 |
| HBD | 3 |
| Rotatable Bonds | 18 |
| Heavy Atoms | 30 |
| LogP | 6.518 |
| Activity (Ki) in nM | 263.027 |
| Polar Surface Area (PSA) | 78.79 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | - |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.80580502 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.72 |
| Ilogp | 4.33 |
| Xlogp3 | 6.74 |
| Wlogp | 5.51 |
| Mlogp | 3.48 |
| Silicos-it log p | 6.65 |
| Consensus log p | 5.34 |
| Esol log s | -5.59 |
| Esol solubility (mg/ml) | 0.00107 |
| Esol solubility (mol/l) | 0.00000255 |
| Esol class | Moderately |
| Ali log s | -8.2 |
| Ali solubility (mg/ml) | 0.00000266 |
| Ali solubility (mol/l) | 6.31E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.79 |
| Silicos-it solubility (mg/ml) | 0.00000692 |
| Silicos-it solubility (mol/l) | 1.64E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.09 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 1 |
| Egan number of violations | 0 |
| Muegge number of violations | 2 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.93 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.163 |
| Logd | 4.344 |
| Logp | 6.51 |
| F (20%) | 0.999 |
| F (30%) | 0.998 |
| Mdck | - |
| Ppb | 98.30% |
| Vdss | 0.685 |
| Fu | 1.49% |
| Cyp1a2-inh | 0.385 |
| Cyp1a2-sub | 0.26 |
| Cyp2c19-inh | 0.748 |
| Cyp2c19-sub | 0.064 |
| Cl | 8.177 |
| T12 | 0.547 |
| H-ht | 0.381 |
| Dili | 0.044 |
| Roa | 0.016 |
| Fdamdd | 0.192 |
| Skinsen | 0.939 |
| Ec | 0.003 |
| Ei | 0.034 |
| Respiratory | 0.025 |
| Bcf | 1 |
| Igc50 | 5.256 |
| Lc50 | 5.007 |
| Lc50dm | 4.886 |
| Nr-ar | 0.694 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.292 |
| Nr-aromatase | 0.242 |
| Nr-er | 0.394 |
| Nr-er-lbd | 0.004 |
| Nr-ppar-gamma | 0.508 |
| Sr-are | 0.445 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.588 |
| Sr-mmp | 0.882 |
| Sr-p53 | 0.429 |
| Vol | 468.011 |
| Dense | 0.9 |
| Flex | 2.714 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.273 |
| Synth | 2.737 |
| Fsp3 | 0.72 |
| Mce-18 | 16 |
| Natural product-likeness | 0.146 |
| Alarm nmr | 1 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |